Abstract
Purpose This systematic review evaluates the current intervention strategies for cystinuria and assesses their quality and efficacy in order to determine the need to identify new and improved strategies for treatment.
Materials and Methods A literature search for interventions in cystinuria was conducted on key electronic databases for studies published between 1996 and 2019. Quality was assessed using Methodological Index for Non-Randomized Studies (MINORS). Studies meeting the inclusion criteria were assessed for study design, patient characteristics and outcomes of interventions, including urinary cystine levels, stone-free rate and stone recurrence rate. A qualitative and critical analysis was performed.
Results Common treatment strategies for cystinuria include hydration and diuresis, alkali therapy and thiol-based therapeutics. Conservative therapies such as adequate hydration and urinary alkalization effectively increased urinary pH, decreased urinary cystine levels and the formation of cystine stones. Second line agents reported included thiols such as Tiopronin, D-penicillamine and captopril. Non-invasive surgical procedures were found to reduce operative trauma and preserved renal function. Combined treatment approaches with hydration and thiols after surgical procedures were associated with less stones and reduced stone recurrence rates. Patient compliance to interventions was often poor and contributed to recurrent cystine stones.
Conclusions Despite existing pharmacological intervention strategies, cystinuria patients frequently require surgical procedures. A more detailed understanding of the mechanisms of pathogenesis of cystinuria as well as an evaluation of patients on an individual basis may be beneficial in reducing the severity of cystinuria, by reducing stone recurrence and associated renal complications.
INTRODUCTION
Cystinuria is a rare inherited autosomal recessive disease. The estimated overall prevalence of cystinuria is 1 in 7,000 births globally, ranging from 1 in 2,500 in Jewish Israelis and 1 in 100,000 in Sweden1-3 Cystinuria accounts for approximately 1-2% of all kidney stone cases in adults and 3-8% in pediatrics.4-8 Cystinuria is characterized by defects in the transport of cystine and other dibasic amino acids including lysine, arginine, and ornithine in both the proximal renal tubules and the small intestine. This defect in transportation result in the accumulation of cystine, which precipitates and forms cystine stones.9 Cystine stones in the kidney and urinary tract, cause inflammation and obstruction and can predispose an individual to the development of chronic kidney disease.
Cystinuria commonly affects children, and the early age of onset, as well as the high stone recurrence rate, in addition to poor compliance with existing interventions, makes this condition difficult to manage.10, 11 Cystinuria is classified into three subtypes denoted type A, type B and type AB. Type A, is caused by mutations in the solute carrier family 3 member 1 (SLC3A1) gene encoding the neutral and basic amino acid transport protein (rBAT) heavy subunit.12, 13 Type B, is caused by mutations in the solute carrier family 7 member 9 (SLC7A9) gene encoding the light subunit b0,+ type amino acid transporter 1 (b0,+AT).13, 14 Type AB occurs when mutations in both SLC3A1 and SLC7A9 genes are present.13 All three types of cystinuria cause defective reabsorption of cystine and dibasic amino acids by the proximal renal tubule.
Despite the recent developments in the understanding of the genetic causes of cystinuria, 13, 15, 16 there is a lack of effective interventions and currently no cure for the disease. Mainstay treatments focus on maintaining cystine homeostasis in the urine. Traditionally, cystinuria management focuses on urinary alkalization using potassium citrate, sodium bicarbonate as well as limiting animal protein intake, whilst maintaining fluid intake to increase urinary volume.17, 18 There are currently very limited randomized controlled trials (RCTs) in cystinuria patients that have assessed stone-related outcomes more than 1 year after intervention. Most of the existing studies report combined intervention approaches such as hydration and diuresis and alkali therapy, as well as pharmacological and surgical interventions.
The thiol-based therapeutics alpha-mercaptopropionylglycine (α-MPG or tiopronin), D-penicillamine and captopril are established pharmacological interventions for cystinuria.17, 19 Complicated stones may require surgical procedures such as extracorporeal shockwave lithotripsy (ESWL), percutaneous nephrolithotomy (PCNL), ureterorenoscopy (URS), retrograde intrarenal surgery (RIRS) and open surgery (OP) to remove cystine stones.10, 11, 20 This review evaluates the existing interventions strategies for cystinuria.
MATERIALS AND METHODS
Literature search
A literature search was conducted on key electronic databases including Medline, Embase, Cochrane, Web of Science, Scopus and Google Scholar. English language articles published between 1996 and December 2019 were included. Manual searching of key journals and conference proceedings were performed to retrieve any additional relevant articles. The following search terms were used individually or in combination; cystinuria, cystine stone, cystine calculi, cystine urolithiasis, cystine nephrolithiasis, cystine, kidney, cystine urine and cystinuria patient. The search terms were defined based on the PICO definition; P (population), I (intervention), O (outcomes), while C (comparison) was only applied where placebo-control and internal-control available in the literature.
Inclusion and exclusion criteria
A diagnosis of cystinuria was based on clinical investigation with at least one previous/current episode of cystine stones, urine cystine levels >250-300mg/L and patients being treated with alkalizing, or pharmacological agents or surgical procedures. The primary outcomes were the type of intervention, change in urinary pH levels, change in urinary cystine levels, stone-free and stone recurrence rates. There were no exclusions based on age, gender, ethnicity, or geographical location. Due to the lack of RCTs for this rare disease, analysis was largely restricted to non-randomized studies with or without control arms. Observational studies including case-control, retrospective and prospective studies were included. Conference abstracts and papers were included if there was sufficient data, and corresponding authors contacted to obtain full study details. Review articles, editorials, news, letters, comments, case series and case reports were excluded. Review articles were used for cross-referencing to retrieve any missing studies and did not contribute to the final number of articles. The inclusion and exclusion criteria were independently applied to all identified articles. Two authors participated in the initial screening of titles and abstracts, and independently screened the titles and abstracts before assessing full text articles. Any disputes were resolved by multiple author agreement. We contacted the authors of the primary reports to request any unclear or unpublished data. If the authors did not reply, the available data was used.
Data Extraction
This systematic review follows Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines.21 References from the database search were pooled into Endnote X8 reference software. Selected data were assessed for study design, aims, inclusion criteria, patient characteristics, intervention strategy and outcomes, renal function data, length of follow-up, stone-free rates, and stone recurrence rates. Intervention studies included alkali therapy, pharmacological agents and surgical procedures outcome comparison at least pre- and post-treatment. The study protocol was registered with PROSPERO to guide this systematic review (ID: CRD42020152061).
Risk of bias (quality) assessment
Most of the available quality assessment tools are designed for the evaluation of RCTs, case-control or cohort studies. Here, the methodological quality assessment tool, Methodological Index for Non-Randomized Studies (MINORS), was used to assess the studies that met the inclusion criteria. MINORS is validated tool applied for the methodological quality of non-comparative and comparative observational studies.22 It consists of 8 items for non-comparative and an additional 4 items for comparative studies. The quality assessment were performed independently by 2 authors (NPB and MRS). AVD, BJF and SHJ cross-checked the selected literature and quality assessment tool to resolve any disputes.
Data synthesis
Due to the anticipated variability in the included studies, and lack of RCTs, meta-analysis was not planned. Hence a qualitative and critical analysis of the data was performed with available patient characteristics, disease history, and treatment procedures and effectiveness. Post-treatment outcomes as mentioned above were compared with patient’s history.
RESULTS
Search results
The initial database and Google search retrieved a total of 1445 articles. After excluding duplicate studies, 660 studies were reviewed for title and abstract screening. 594 were excluded due to being non-relevant (500), a review (34), case reports (48), animal studies (4), supplementary comments (3), non-English (2) or published prior to 1996 (3). A total of 66 studies underwent full-text review. 40 articles were excluded after screening the full text; non-relevant studies (20), inappropriate study aims or outcomes (15) or full text not available (5). 24 studies met the review criteria and the MINORS quality assessment tool was applied to these studies, which resulted in the exclusion of 2 studies that did not meet the quality control requirements (Figure 1).
Study characteristics
A summary of the study characteristics is provided in Table 1. 17 studies were retrospective observational studies and 7 were prospective observational studies, with or without comparison groups. Of the 24 total studies, 11 were non-comparative studies and 13 were comparative studies. The quality of the included studies were assessed using the MINORS score (Table 2 and 3). The mean score for non-comparative studies was 11 out of 16 (range, 8-13). For non-comparative studies MINORS scores are classified as: low (score 5-8), moderate (score 9-12), and high quality (score 13-16). The mean score for comparative studies was 17 out of 24 (range, 12-21). For comparative studies MINORS scores are classified as: low (score 7-12), moderate (score 13-18) and high quality (score 19-24). Those studies that scored a moderate or high MINORS score were included. 2 studies were excluded due to a low MINORS score.
Of the 24 studies, 18 reported outcomes from alkalinizing compounds (potassium citrate and sodium bicarbonate) and/or thiol drugs (D-penicillamine, tiopronin and captopril).10, 11, 17-20, 23-34 20 studies reported outcomes from surgical interventions in cystinuria patients.10, 11, 17-20, 24-26, 29, 30, 32-40 Of the 24 studies, 15 reported combined intervention methods with alkalinizing compounds, pharmacological drugs and/or surgical procedures.10, 11, 17-20, 24-27, 29, 30, 32-34 No studies directly compared pharmacological intervention to surgical intervention.
In this review, a total of 654 cystinuria patients (mean 27.25 per study) were included. Among these patients, 323 were male (53%) and 286 (47%) were female, from 21 studies. 3 studies did not distinguish patient’s gender. 19 studies reported mean patient age, which ranged from 7.4 to 49 years.10, 17-20, 23-28, 31, 32, 34-38, 40 Of the 24 studies, 5 reported median patient age, which ranged from 6 to 18.5 years.11, 29, 30, 33, 39
Effectiveness of urine dilution and alkalization
Initial treatment for cystinuria is to maintain daily urine volume >3L/day.17 In addition to appropriate hydration, urinary alkalization is used to maintain urinary pH >6.5.18 Of the 24 studies, 16 reported the use of potassium citrate and sodium bicarbonate as an alkalizing agents for the management of cystinuria.10, 11, 17-20, 24-27, 29-34 5 studies reported the detail concentration of alkalizing agents used and their outcome of treatment (Table 4).11, 17, 18, 26, 32 Potassium citrate (1mEq/kg/day,11, 30 40-70mmol/day,18 1000mg three times/day32) and sodium bicarbonate (8-18gm/kg/day,17 47.6-107mmol/day,18 500mg four times/day32) were recommended for all patients after cystinuria diagnosis. A significant increase in urinary pH was observed with sodium bicarbonate treatment (6.4-7.25, p<0.01),18 and potassium citrate treatment (6.4-7.10, p<0.05),18 (5.6-6.9, p=0.02)11 and (5.8-7.55, p<0.001).26 Post-treatment urinary pH levels were increased >7 with treatment of potassium citrate and sodium bicarbonate.17, 32
Cystinuria patients excrete less citrate (262±428mg/1.73/m3) than healthy controls (491±490mg/1.73/m3, p=0.044) with urinary citrate excretion in the pre-treatment group lower (255±219mg./1.73/m3) than the post-treatment group (729±494mg./1.73/m3, p=0.003).11 Urinary citrate excretion was also increased by alkalization therapy (2.9±1.1-5.4±1.3mmol/day, p<0.01).17
Urinary sodium excretion was significantly increased (144mmol/day-220mmol/day, p<0.05)18 and (173±58mmol/day-263±91mmol/day, p<0.001)17 by sodium bicarbonate treatment. Urinary potassium excretion (63mmol/day-94mmol/day, p<0.01) were also significantly increased during treatment with potassium citrate.18
Effectiveness of pharmacological interventions
17 studies reported pharmacological intervention using the thiol-based drugs; tiopronin, D-penicillamine and captopril.10, 11, 17-20, 23-25, 27-34 These interventions were applied when hydration and alkalization treatment was not effective in reducing urinary pH and cystine levels. Of the 17 studies, 12 reported urinary pH change, urinary cystine levels, number of stones per patient-year and stone free rate (Table 5).11, 17, 19, 23-25, 27-32
7 studies reported an association between pharmacological interventions and urinary cystine excretion, along with additional outcomes such as the number of stone episodes, the number of surgical procedures, stone recurrence rate and stone-free rate.11, 17, 23, 24, 27, 28, 31 Urinary cystine decreased from 1,052±161mg/day to 755±81mg/day with tiopronin treatment, and from 789±126mg/day to 517±92mg/day with D-penicillamine in the mean patients age of 19.6 years. However, captopril did not change cystine excretion (1,044±57mg/day to 1,039±137mg/day).17 A significant difference was reported between patients treated with hyperdiuresishyper-diuresis and alkalization, and added thiols (808±305mg/24hrs vs 585±128mg/24hrs, p=0.046).17 The average urinary cystine levels were reduced by 54% (range, 5-81%) with D-penicillamine (20mg/kg/day),23 and 15% of cystinuria patients maintained urinary cystine excretion <300mg/L following tiopronin (1000mg/day) treatment.31 Further, two studies reported a significant reduction in urinary cystine levels (p=0.015)11 and (p<0.039)28 following intervention with tiopronin and/or D-penicillamine. Decreased urine cystine level (221.2±75.2mg/L) was reported when stone events <0.3 per year compared to increased urine cystine level (303.3±93.5mg/L) when stone events ≥0.3 per year).27 Cystinuria patients had less urinary citrate excretion compared to the control group (262±428mg/1.73/m3-491±490mg/1.73/m3, p=0.044), however, citrate excretion was increased (p=0.003) after intervention with tiopronin (10-15mg/kg/day).11
Cystinuria patients with alkalization and thiol intervention had up to a 65% reduction in yearly stone events, which equated to 2.7 per patient or 0.52 stone events per patient-year.19 Tiopronin (13.8-51mg/kg/day) and D-penicillamine (16.3-17.8mg/kg/day) reduced stone events from 0.28 to 0.03 per year.24 Stone free rates ranged from 22 to 87% with diuresis, alkalization and pharmacological management after single or multiple surgical procedures.11, 17, 19, 25, 27, 29, 30, 32 Thiol-treated patients had decreased stone recurrence when urinary cystine excretion was maintained at <797 mg/gm creatinine/24 hours.25
Effectiveness of surgical interventions
Surgical intervention strategies for cystine stones include ESWL, PCNL, URS, RIRS and OP. Either single or combined surgical procedures were partially effective in removing stones.10, 11, 17-20, 24-26, 29, 30, 32-40 Ahmed et al. reported cystine stone patients needed repeated surgical procedures to remove stones including ESWL which accounted for 61%, URS 21%, PCNL 12% and OP 6% of surgical procedures.10 Another study reported ESWL 26%, PCNL 12%, RIRS 6% and OP 53% surgical procedures were required to remove cystine stones.17 Typically, males required more surgical procedures than females (2.9 vs 2.5).32
Of the 20 studies, 13 reported detail about intervention type, stone position, intervention procedure, stone free rate and stone recurrence rate (Table 6).10, 11, 17, 19, 20, 25, 29, 30, 32, 33, 36, 38, 39 The type of surgical treatment selected was dependent on the size and location of the stones. 5 studies reported various stone positions from unilateral, bilateral, left and right kidney, calyceal, pelvic and ureteral cystine stones.17, 19, 30, 32, 33 Bilateral cystine stones were associated with a higher number of lifetime stone surgeries than unilateral stones (6.5 vs 2 sessions, p<0.05).33 Stones were found in the left (46%) and right (54%) kidney.30 Furthermore, 41% calyceal, 55% ureter and 4% pelvic stones were present in patients with cystinuria.32
Stone events were 2.4,17 3.2,32 4.210 and 5.519 per patient for the treatment period in 4 studies. Total surgical procedures ranged from 0.84 to 7.9 per patient.10, 17, 19, 25, 29, 32, 33, 36, 39 Further surgical procedures vaired from 0.29 to 1 per patient-year in 6 studies.11, 17, 19, 33, 38, 39 67% of cystinuria patients had their stones removed after a single or combined ESWL, PCNL and OP intervention, and 33% still had residual stones even after surgery. The overall stone recurrence rate was 0.64 per patient-year.11 There were no differences between less-invasive and traditional surgical procedures with surgical procedures per patient-year (1.34 vs 1.16) and stone recurrence rate (0.111 vs 0.493), respectively.38
10 studies reported the percentage of stone-free patients after the first surgical procedures which varied from 22% to 100%.10, 11, 17, 19, 20, 25, 30, 32, 36 Stone-free rate was dependent on the type of intervention used; PNCL (85%) was more successful than other procedures, however, stone free status was not linked to probability of recurrence of stones.25 Stone free rate after first PCNL was 0% in cystine stone group and 40% in struvite stone group, and final stone free rate after a secondary procedure was increased to 70% in cystine stone group and 80% in struvite stone group.40 RIRS had a 100% stone free rate and it was considered a safe intervention in pediatric cystine stone management.20
5 studies reported pharmacological interventions and stone recurrence in cystinuria patients, which ranged from 31 to 78%.11, 17, 25, 29, 30 Overall stone recurrence was 41.1% during mean follow-up period of 2.5 years and recurrence rate was decreased to 16.6% for medical prophylaxis, although, 100% recurrence for non-prophylaxis cystinuria patients.26 Stone recurrence was 3.2 per patient during the 5 years of follow-up and number of surgical intervention was 2.7 per patient.32 The recurrence rate after achieving stone-free status with surgical treatment was 31.2%, and the regrowth rate for children with residual stones was 29.4%.30 Moore et al., reported 62.5% of cystinuria patients had recurring stones during the mean follow-up period of 8.6 years and lower stone recurrence rate in patients who had stone-free status following their first treatment compared to stone-free status following multiple sessions (p=0.091).29
Comparison between cystine and non-cystine stone patients
4 studies reported comparisons between cystine and non-cystine patients (Table 7).34, 35, 37, 40 Cystine stones occurred in early age compared to calcium oxalate (CaOx) stones (15.0±11.1years vs 33.5±14.8years, p<0.001), and were larger in size compared with CaOx stones (24.6±11.0mm vs 15.2±8.25mm, p<0.001).37 2 studies reported cystine stone patient required higher surgical procedures than CaOx stone patients (14.1% vs 2.96%, p=0.00735 and 9.80±9.17 vs 2.73±1.95, p<0.00137). Cystine stone patients underwent significantly more surgical procedures than non-cystine stone patients (4.0 vs 1.86, p<0.001).34 Similar findings were reported by Yamacake et al., where cystine stone patients required higher surgical procedures than struvite stone patients (3.57±1.04 vs 2.0±1.22, p=0.028).40
The average number of surgical procedures in cystinuria patients was 3.1 (range 1-8/patient).29 Thiol intervention decreased the number of required surgical procedures from 0.88 to 0.23 (p<0.001) during the follow-up period.34 Furthermore, SWL (1.18±1.56 and 0.73±1.02, p=0.0001), PCNL (0.93±1.18 and 0.09±0.47, p=0.00001) and OP (0.92±1.21 and 0.16±0.55, p=0.0001) procedures were reported for cystine stone than CaOx stone patients.35 Similar findings were reported by Sfoungaristos et al., with cystinuria patients more frequently receiving SWL (6.33±6.63 vs 1.63±1.73, p<0.001) and PCNL (1.53±1.41 vs 0.37±0.49, p<0.001) than CaOx stone patients.37 Overall the number of surgical procedures to remove stones was higher in cystine stone patients than CaOx stone patients (9.80±9.17 vs 2.73±1.95, p<0.001).37
Patient compliance and treatment outcomes
The management and outcomes of cystinuria patients depends on patient compliance. 3 studies reported patient compliance with follow-up protocols based on their diet, medication regimen and frequency of patient visits to the clinic/doctor following intervention.32, 36, 37 Medical compliance after the diagnosis of cystine stones was 64.3% and overall success of the treatment was 64.2%.32 A monthly, quarterly and semi-annual clinic visit was required for medical evaluation of cystinuria patients, and stone-free rates were higher (73%) in patients that were compliant to treatment compared to non-compliant patients (33%).36 The average number of surgical interventions was 1.0 in compliant patients compared to 4.0 in non-compliant patients (p<0.05).36 The average serum creatinine (1.02mg/dL vs 1.1mg/dL, p=0.32) and urinary cystine excretion (282.2±52.6mg/L vs 382.4±61.3mg/L, p=0.25), and urinary pH (7.4±0.2 vs 7.1±0.3, p=0.66) were different for compliant and non-compliant cystinuria patients.36 There were lower compliance rates to diet (30 vs 62.5%) and medical treatment (64.3 vs 85.7%) for cystine stone patients compared with CaOx stone patients.37 Cystinuria patient compliance was associated with side effects of pharmacological agents and surgical procedures.37
DISCUSSION
In this systematic review, we synthesized the results from the observational studies of existing intervention approaches for cystinuria including hydration and diuresis, alkalization, pharmacological and surgical procedures. The initial management of cystinuria patients includes hydration and urine alkalization to decrease urinary cystine levels to <250-300mg/L. Fluid intake should maintain urine volume >3L/day. Potassium citrate and sodium bicarbonate can then be used to increase urine pH >6.5, and cystine excretion to <250mg/L.11, 18 Additional pharmacological interventions are introduced if cystinuria patients do not respond to hydration and alkalization therapy. These additional interventions typically include treatment with tiopronin, D-penicillamine and captopril.19 Pharmacological treatments are effective in lowering urinary cystine levels ultimately decreasing stone events, stone recurrence rate, and increasing stone free rates in cystinuria patients.11, 17, 19, 23-25, 27-29, 31 While alkalization and pharmacological interventions are somewhat effective at decreasing stone episodes, these interventions are often poor at reducing cystine stone recurrence. Therefore, cystinuria patients often require surgical interventions to decrease stone recurrence rates and stone growth. To maintain a stone-free status, combined approaches of thiol-drugs and surgical procedures are required.10, 11 Multiple studies report that cystinuria patients require significantly higher numbers of surgical interventions than other urinary stone patients.34, 35, 37, 40 A greater number of ESWL, PCNL and OP procedures were required for cystine stones than CaOx stones and patients were at increased risk for renal impairment and loss of renal function.35, 37 PCNL was the most successful surgical procedure for achieving stone-free status in cystinuria patients.25 PCNL is also a safe and effective treatment for children with cystine stones.30 Although existing interventions are useful for reducing cystine stones, patient compliance with pharmacological medications is poor due to adverse side effects and high recurrence rates of cystine stones. Hence, management of cystine stones requires improved intervention approaches to reduce stone recurrence rates.38
Current treatment strategies for cystinuria are focused on relieving symptoms and preventing the formation of cystine stones. It is accepted that increasing fluid intake, regular monitoring of urinary pH and reduced dietary methionine and salt intake can reduce urinary cystine concentration.41 This can be achieved by high fluid consumption that increases urine volume to wash out cystine crystals, and alkalinizing supplements that maintain urine pH >6.5 to inhibit cystine aggregation and reduce cystine stone development.18 Usually, cystine is poorly soluble between pH 5-6.5 and cystine stones formed when individual cystine excretion in urine is exceeding 240-300mg/L (1.33-1.66mmol/L).1 Therefore, urine pH of >6.5 may help the dissolution of stones.18 Hence, urinary pH must be routinely monitored. Hydration and alkalization therapies prescribed according to body weight and severity of disease may improve quality of life of cystinuria patients by controlling urinary cystine concentration.
Thiol-based drugs are capable of breaking the disulfide bond of cystine producing cysteine, which is more soluble in urine and inhibits stone formation.1 These thiol drugs combine with cystine to form a soluble disulfide complex that prevents stone formation and promotes stone dissolution. Tiopronin, D-penicillamine and captopril are the most commonly reported thiol drugs for cystine stone management. Tiopronin has been shown to have high efficacy and less side effects compared with D-penicillamine and captopril.42, 43 D-penicillamine is equally effective, although tiopronin has a lower incidence of side effects compared to D-penicillamine. Typically, 75-100mg captopril is effective in patients who are non-responsive to standard treatment and in associated hypertensive cystinuria patients, but does increase the risk of worsening chronic kidney disease.41 Approximately 50% of cystinuria patients experience adverse effects to these medications including gastrointestinal intolerance, nephrotic syndrome, rash and leukopenia, which impacts on patient compliance to these intervetions.41
Surgical interventions for cystine stones are the same as those considered for other urinary stones,41 although those experiencing cystine stones are more likely to undergo surgical interventions more often due to the higher rate of reoccurrence.35, 40 The most common surgical interventions that are recommended for cystinuria include ESWL, PCNL, URS, RIRS and OP. ESWL is an effective treatment for cysteine stones smaller than 2.5 cm whereas PCNL is most useful for larger stones.44 During the surgical interventions, ESWL increased stone free rates in cystinuria patients, however, it is still lower than non-cystine stone patinets.34 Due to the composition of cystine stones and the amino acid structure, most of patient require multiple ESWL to dissolve of the stones. ESWL is effective and less invasive treatment of cystinuria preventing long-term complications of recurrent cystine stones.45 On the other hand, PCNL is considered a better surgical treatment of larger cystine stones where ESWL is less effective. However, PCNL is improved with ureteroscopic design and can be considered for larger and more complex stones. To achieve high stone-free rates, the majority of stones can be treated by ESWL, PCNL, URS, RIRS or OP alone or in combination.11, 44 URS is minimally invasive procedure usually done when ureter is examined for stone identification and this procedure is effective to observe cystine stone during blockage or stone pass out through urinary tract.39 URS is very safe and effective for recurrent cystine stone to perform precise surgical intervention to stone clearance.46 Most studies suggest RIRS is the most commonly used procedure and is a safe operative intervention. RIRS is effective, minimally invasive, safe treatment procedure in pediatric with 100% stone free rate.20 Usually, RIRS is used as an initial procedure more often in children, whereas ESWL and PCNL are more common procedures in adults.47 OP is restricted to when ESWL, PCNL, URS, RIRS alone or combined are not effective. OP procedures are recommended for complex staghorn and multiple stones, where other treatment strategies fail. PCNL and RIRS are safe and effective treatment procedures for pediatric cystine stone patients.20, 30
This review has several limitations, including the heterogeneity among selected studies including sample size and the short follow up time of the selected studies. Typically, RCTs are selected for systematic reviews because of their validity and strong outcomes. In this review, half of the available literature are retrospective studies without a control group. Due to the lack of RCTs studies in cystinuria, owing to the condition being rare, this review included all interventional studies having meaningful outcomes. Serum cystine levels and urinary cystine levels were not available for all included studies. Indeed, further RCTs are required for assessing the effectiveness of interventions in cystinuria.
CONCLUSIONS
This systematic review highlights that cystinuria is a challenging disease to treat, requiring a range and/or combination of intervention strategies including hydration, alkalization, pharmacological and surgical procedures. Cystinuria patients have a high rate of cystine stone recurrence. New emerging therapies based on a more detailed understanding of cystinuria pathogenesis and treatment should focus to reducing recurrent stones, decreasing side effects, and preservation of renal function. The currently available observational studies do not have enough interventional details and long-term (>1 year) follow up, and most contain retrospective data without control groups. RCTs with long-term follow up and large sample size would be the appropriate design to obtain clear outcomes for optimal treatment strategies for cystinuria. The future successful management of cystinuria patients will require improved strategies for patient compliance and better treatment outcomes.
Data Availability
All data used in this systematic review is available online through relevant cited references
